Cargando…
Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis
OBJECTIVE: We conducted a pooled analysis of published studies to compare the performance of human papillomavirus (HPV) testing and cytology in detecting residual or recurrent diseases after treatment for cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3). METHODS: Source articles presenting...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695453/ https://www.ncbi.nlm.nih.gov/pubmed/26463429 http://dx.doi.org/10.3802/jgo.2016.27.e3 |
_version_ | 1782407639101079552 |
---|---|
author | Onuki, Mamiko Matsumoto, Koji Sakurai, Manabu Ochi, Hiroyuki Minaguchi, Takeo Satoh, Toyomi Yoshikawa, Hiroyuki |
author_facet | Onuki, Mamiko Matsumoto, Koji Sakurai, Manabu Ochi, Hiroyuki Minaguchi, Takeo Satoh, Toyomi Yoshikawa, Hiroyuki |
author_sort | Onuki, Mamiko |
collection | PubMed |
description | OBJECTIVE: We conducted a pooled analysis of published studies to compare the performance of human papillomavirus (HPV) testing and cytology in detecting residual or recurrent diseases after treatment for cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3). METHODS: Source articles presenting data on posttreatment HPV testing were identified from the National Library of Medicine (PubMed) database. We included 5,319 cases from 33 articles published between 1996 and 2013. RESULTS: The pooled sensitivity of high-risk HPV testing (0.92; 95% confidence interval [CI], 0.90 to 0.94) for detecting posttreatment CIN 2 or worse (CIN 2+) was much higher than that of cytology (0.76; 95% CI, 0.71 to 0.80). Co-testing of HPV testing and cytology maximized the sensitivity (0.93; 95% CI, 0.87 to 0.96), while HPV genotyping (detection of the same genotype between pre- and posttreatments) did not improve the sensitivity (0.89; 95% CI, 0.82 to 0.94) compared with high-risk HPV testing alone. The specificity of high-risk HPV testing (0.83; 95% CI, 0.82 to 0.84) was similar to that of cytology (0.85; 95% CI, 0.84 to 0.87) and HPV genotyping (0.83; 95% CI, 0.81 to 0.85), while co-testing had reduced specificity (0.76; 95% CI, 0.75 to 0.78). For women with positive surgical margins, high-risk HPV testing provided remarkable risk discrimination between test-positives and test-negatives (absolute risk of residual CIN 2+ 74.4% [95% CI, 64.0 to 82.6] vs. 0.8% [95% CI, 0.15 to 4.6]; p<0.001). CONCLUSION: Our findings recommend the addition of high-risk HPV testing, either alone or in conjunction with cytology, to posttreatment surveillance strategies. HPV testing can identify populations at greatest risk of posttreatment CIN 2+ lesions, especially among women with positive section margins. |
format | Online Article Text |
id | pubmed-4695453 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-46954532016-01-01 Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis Onuki, Mamiko Matsumoto, Koji Sakurai, Manabu Ochi, Hiroyuki Minaguchi, Takeo Satoh, Toyomi Yoshikawa, Hiroyuki J Gynecol Oncol Original Article OBJECTIVE: We conducted a pooled analysis of published studies to compare the performance of human papillomavirus (HPV) testing and cytology in detecting residual or recurrent diseases after treatment for cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3). METHODS: Source articles presenting data on posttreatment HPV testing were identified from the National Library of Medicine (PubMed) database. We included 5,319 cases from 33 articles published between 1996 and 2013. RESULTS: The pooled sensitivity of high-risk HPV testing (0.92; 95% confidence interval [CI], 0.90 to 0.94) for detecting posttreatment CIN 2 or worse (CIN 2+) was much higher than that of cytology (0.76; 95% CI, 0.71 to 0.80). Co-testing of HPV testing and cytology maximized the sensitivity (0.93; 95% CI, 0.87 to 0.96), while HPV genotyping (detection of the same genotype between pre- and posttreatments) did not improve the sensitivity (0.89; 95% CI, 0.82 to 0.94) compared with high-risk HPV testing alone. The specificity of high-risk HPV testing (0.83; 95% CI, 0.82 to 0.84) was similar to that of cytology (0.85; 95% CI, 0.84 to 0.87) and HPV genotyping (0.83; 95% CI, 0.81 to 0.85), while co-testing had reduced specificity (0.76; 95% CI, 0.75 to 0.78). For women with positive surgical margins, high-risk HPV testing provided remarkable risk discrimination between test-positives and test-negatives (absolute risk of residual CIN 2+ 74.4% [95% CI, 64.0 to 82.6] vs. 0.8% [95% CI, 0.15 to 4.6]; p<0.001). CONCLUSION: Our findings recommend the addition of high-risk HPV testing, either alone or in conjunction with cytology, to posttreatment surveillance strategies. HPV testing can identify populations at greatest risk of posttreatment CIN 2+ lesions, especially among women with positive section margins. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2016-01 2015-10-08 /pmc/articles/PMC4695453/ /pubmed/26463429 http://dx.doi.org/10.3802/jgo.2016.27.e3 Text en Copyright © 2016. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Onuki, Mamiko Matsumoto, Koji Sakurai, Manabu Ochi, Hiroyuki Minaguchi, Takeo Satoh, Toyomi Yoshikawa, Hiroyuki Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis |
title | Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis |
title_full | Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis |
title_fullStr | Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis |
title_full_unstemmed | Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis |
title_short | Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis |
title_sort | posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695453/ https://www.ncbi.nlm.nih.gov/pubmed/26463429 http://dx.doi.org/10.3802/jgo.2016.27.e3 |
work_keys_str_mv | AT onukimamiko posttreatmenthumanpapillomavirustestingforresidualorrecurrenthighgradecervicalintraepithelialneoplasiaapooledanalysis AT matsumotokoji posttreatmenthumanpapillomavirustestingforresidualorrecurrenthighgradecervicalintraepithelialneoplasiaapooledanalysis AT sakuraimanabu posttreatmenthumanpapillomavirustestingforresidualorrecurrenthighgradecervicalintraepithelialneoplasiaapooledanalysis AT ochihiroyuki posttreatmenthumanpapillomavirustestingforresidualorrecurrenthighgradecervicalintraepithelialneoplasiaapooledanalysis AT minaguchitakeo posttreatmenthumanpapillomavirustestingforresidualorrecurrenthighgradecervicalintraepithelialneoplasiaapooledanalysis AT satohtoyomi posttreatmenthumanpapillomavirustestingforresidualorrecurrenthighgradecervicalintraepithelialneoplasiaapooledanalysis AT yoshikawahiroyuki posttreatmenthumanpapillomavirustestingforresidualorrecurrenthighgradecervicalintraepithelialneoplasiaapooledanalysis |